BioNTech SE (NASDAQ:BNTX) Receives Average Recommendation of “Moderate Buy” from Analysts

BioNTech SE (NASDAQ:BNTX) has earned an average recommendation of “Moderate Buy” from the eighteen analysts that are presently covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a hold recommendation, fourteen have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $142.08.

A number of analysts have weighed in on BNTX shares. Canaccord Genuity Group restated a “buy” rating and set a $171.44 price objective on shares of BioNTech in a research note on Tuesday, March 11th. HC Wainwright restated a “buy” rating and set a $134.00 target price (down previously from $145.00) on shares of BioNTech in a research report on Wednesday, May 14th. Morgan Stanley cut their price objective on shares of BioNTech from $140.00 to $132.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 6th. BMO Capital Markets upped their price target on shares of BioNTech from $130.00 to $143.00 and gave the company an “outperform” rating in a research note on Tuesday, March 11th. Finally, Citigroup reiterated a “buy” rating and issued a $140.00 target price (down previously from $145.00) on shares of BioNTech in a research report on Tuesday, May 6th.

Institutional Trading of BioNTech

Large investors have recently modified their holdings of the stock. FMR LLC increased its position in BioNTech by 22.2% during the 4th quarter. FMR LLC now owns 7,701,476 shares of the company’s stock worth $877,583,000 after purchasing an additional 1,401,547 shares in the last quarter. Flossbach Von Storch SE grew its position in BioNTech by 1.1% in the 4th quarter. Flossbach Von Storch SE now owns 4,406,843 shares of the company’s stock valued at $502,160,000 after purchasing an additional 47,236 shares during the period. Capital International Investors lifted its holdings in shares of BioNTech by 38.6% in the fourth quarter. Capital International Investors now owns 1,415,566 shares of the company’s stock valued at $161,304,000 after purchasing an additional 394,434 shares in the last quarter. BNP Paribas Financial Markets boosted its holdings in BioNTech by 94.6% during the first quarter. BNP Paribas Financial Markets now owns 1,195,470 shares of the company’s stock worth $108,859,000 after purchasing an additional 581,173 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its position in shares of BioNTech by 18,892.9% during the 1st quarter. Bank of New York Mellon Corp now owns 698,368 shares of the company’s stock valued at $63,593,000 after purchasing an additional 694,691 shares during the last quarter. 15.52% of the stock is owned by institutional investors and hedge funds.

BioNTech Price Performance

BioNTech stock opened at $101.72 on Wednesday. The business has a fifty day moving average price of $97.45 and a 200-day moving average price of $108.67. The firm has a market capitalization of $24.45 billion, a P/E ratio of -48.44 and a beta of 1.35. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. BioNTech has a one year low of $76.53 and a one year high of $131.49.

BioNTech (NASDAQ:BNTX) last released its earnings results on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.70. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The company had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.24 billion. During the same quarter in the previous year, the company posted $1.90 EPS. BioNTech’s revenue for the quarter was down 19.5% on a year-over-year basis. As a group, equities research analysts forecast that BioNTech will post -3.88 EPS for the current year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.